1 / 12

S ystolic H eart failure treatment with the I f inhibitor ivabradine T rial

S ystolic H eart failure treatment with the I f inhibitor ivabradine T rial. Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy. www.shift-study.com.

lydia
Download Presentation

S ystolic H eart failure treatment with the I f inhibitor ivabradine T rial

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Systolic Heart failure treatment withthe Ifinhibitor ivabradine Trial Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy www.shift-study.com Tardif JC, O'Meara E, Komajda M, et al. Eur Heart J. 2011;32(20):2507-15

  2. Background • Cardiac remodeling is central to the pathophysiology of heart failure (HF) and is a prognostic factor in patients with HF • Left ventricular (LV) enlargement and reduced ejection fraction are powerful predictors of outcomes in heart failure • Therapeutic effects of drugs and devices on LV remodeling are associated with their longer-term effects on mortality www.shift-study.com Tardif JC, O'Meara E, Komajda M, et al. Eur Heart J. 2011;32(20):2507-15

  3. Objective of the pre-specified echocardiography substudy • To evaluate the effects of the If inhibitor ivabradine on LV remodeling and function: • Primary endpoint: the change in the LV end-systolic volume index (LVESVI) from baseline to 8 months • Secondary endpoints: changes during the same interval in • LV end-diastolic volume index (LVEDVI) • LV end-systolic, end-diastolic volumes (LVESV, LVEDV) • LV ejection fraction (LVEF) www.shift-study.com Tardif JC, O'Meara E, Komajda M, et al. Eur Heart J. 2011;32(20):2507-15

  4. Sub-study population 611 patients included from 89 centers in 21 countries 307 patients Placebo 304 patients Ivabradine Excluded (N=104) Excluded (N=96) 52: Poor quality of echo recording 19: No baseline and/or 8-month recording 8: Non-matching biplane or 4-chamber views 13: Withdrawn due to death 4: Consent withdrawn 52: Poor quality of echo recording 15: No baseline and/or 8- month recording 1: Non-matching biplane or 4-chamber views 23: Withdrawn due to death 13: Consent withdrawn 208 patients Ivabradine 203 patients Placebo Median follow-up after 8-month echocardiogram: 16.1 months www.shift-study.com Tardif JC, O'Meara E, Komajda M, et al. Eur Heart J. 2011;32(20):2507-15

  5. Baseline characteristics www.shift-study.com Tardif JC, O'Meara E, Komajda M, et al. Eur Heart J. 2011;32(20):2507-15

  6. Baseline background treatment www.shift-study.com Tardif JC, O'Meara E, Komajda M, et al. Eur Heart J. 2011;32(20):2507-15

  7. LV end-systolic volume index and outcome in the placebo group Patients with primary composite endpoint, % HR 1.62, p=0.04 60 LVESVI > 59 mL/m2 40 LVESVI < 59 mL/m2 20 www.shift-study.com Tardif JC, O'Meara E, Komajda M, et al. Eur Heart J. 2011;32(20):2507-15

  8. Primaryendpoint: change in LVESVIfrombaseline to 8 months Left ventricular end-systolic volume index ∆ -5.8,P<0.001 75 70 D- 7.0 ± 16.3 D - 0.9 ± 17.1 65 mL/m2 60 63.6 ±30.1 65.2±29.1 62.8 ±28.7 58.2±28.3 55 50 0 Baseline 8 months Baseline 8 months Ivabradine (n=208) Placebo (n=203) www.shift-study.com Tardif JC, O'Meara E, Komajda M, et al. Eur Heart J. 2011;32(20):2507-15

  9. D-7.9 ± 18.9 D -1.8 ± 19.0 Secondaryendpoint: change in LVEDVI frombaseline to 8 months Left ventricular end-diastolic volume index ∆ -5.5, P=0.002 100 95 90 mL/m2 85 90.8 ±33.1 89.0±31.6 93.9 ±32.8 85.9 ±30.9 80 75 0 Baseline 8 months Baseline 8 months Ivabradine (n=204) Placebo (n=199) www.shift-study.com Tardif JC, O'Meara E, Komajda M, et al. Eur Heart J. 2011;32(20):2507-15

  10. D2.4 ± 7.7 D - 0.1 ± 8.0 M008 M008 Baseline Baseline Secondary endpoint: change in LVEF from baseline to 8 months ∆ + 2.7,P<0.001 Left ventricular ejection fraction 40 35 30 65.2 ± 29.1 25 31.6 ±9.3 31.5±10.0 32.3±9.1 34.7±10.2 % 20 15 10 5 0 Baseline 8 months Baseline 8 months Ivabradine (n=204) Placebo (n=199) www.shift-study.com Tardif JC, O'Meara E, Komajda M, et al. Eur Heart J. 2011;32(20):2507-15

  11. Summary of changes in HR, LV end-systolic/end-diastolic volume indexes www.shift-study.com Tardif JC, O'Meara E, Komajda M, et al. Eur Heart J. 2011;32(20):2507-15

  12. Conclusions • Heart rate reduction with ivabradine reverses left ventricular remodeling in patients with heart failure and LV systolic dysfunction: • Marked reductions of LV volumes • Significant improvement of LV ejection fraction • These results suggest that ivabradine modifies disease progression in patients with HF receiving background therapy www.shift-study.com Tardif JC, O'Meara E, Komajda M, et al. Eur Heart J. 2011;32(20):2507-15

More Related